Jeong Ji Hun, Seo Yiel Hea, Ahn Jeong Yeal, Kim Kyung Hee, Seo Ja Young, Kim Moon Jin, Lee Hwan Tae, Park Pil Whan
Department of Laboratory Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Ann Lab Med. 2016 Sep;36(5):420-6. doi: 10.3343/alm.2016.36.5.420.
Amino-terminal pro-B type natriuretic peptide (NT-proBNP) is a well-established prognostic factor in heart failure (HF). However, numerous causes may lead to elevations in NT-proBNP, and thus, an increased NT-proBNP level alone is not sufficient to predict outcome. The aim of this study was to evaluate the utility of two acute response markers, high sensitivity C-reactive protein (hsCRP) and heart-type fatty acid binding protein (H-FABP), in patients with an increased NT-proBNP level.
The 278 patients were classified into three groups by etiology: 1) acute coronary syndrome (ACS) (n=62), 2) non-ACS cardiac disease (n=156), and 3) infectious disease (n=60). Survival was determined on day 1, 7, 14, 21, 28, 60, 90, 120, and 150 after enrollment.
H-FABP (P<0.001), NT-proBNP (P=0.006), hsCRP (P<0.001) levels, and survival (P<0.001) were significantly different in the three disease groups. Patients were divided into three classes by using receiver operating characteristic curves for NT-proBNP, H-FABP, and hsCRP. Patients with elevated NT-proBNP (≥3,856 pg/mL) and H-FABP (≥8.8 ng/mL) levels were associated with higher hazard ratio for mortality (5.15 in NT-proBNP and 3.25 in H-FABP). Area under the receiver operating characteristic curve analysis showed H-FABP was a better predictor of 60-day mortality than NT-proBNP.
The combined measurement of H-FABP with NT-proBNP provides a highly reliable means of short-term mortality prediction for patients hospitalized for ACS, non-ACS cardiac disease, or infectious disease.
氨基末端B型利钠肽原(NT-proBNP)是心力衰竭(HF)中公认的预后因素。然而,多种原因可导致NT-proBNP升高,因此,仅NT-proBNP水平升高不足以预测预后。本研究的目的是评估两种急性反应标志物,即高敏C反应蛋白(hsCRP)和心型脂肪酸结合蛋白(H-FABP),在NT-proBNP水平升高患者中的应用价值。
278例患者按病因分为三组:1)急性冠状动脉综合征(ACS)(n=62),2)非ACS心脏病(n=156),3)传染病(n=60)。在入组后第1、7、14、21、28、60、90、120和150天确定生存率。
三组疾病的H-FABP(P<0.001)、NT-proBNP(P=0.006)、hsCRP(P<0.001)水平和生存率(P<0.001)有显著差异。利用NT-proBNP、H-FABP和hsCRP的受试者工作特征曲线将患者分为三类。NT-proBNP(≥3856 pg/mL)和H-FABP(≥8.8 ng/mL)水平升高的患者死亡风险比更高(NT-proBNP为5.15,H-FABP为3.25)。受试者工作特征曲线下面积分析显示,H-FABP比NT-proBNP更能预测60天死亡率。
H-FABP与NT-proBNP联合检测为因ACS、非ACS心脏病或传染病住院的患者提供了一种高度可靠的短期死亡率预测方法。